Research Of The Relation Between MBL And Type 2 Diabetic Pations With Macrovascular Complications

Objective: Complement activation flammation have been suggested in the pathogenesis of diabetes vascular lesions. Method: 1. We investigated polymorphisms in the MBL gene, serum mannose-binging lectin(MBL) levels and serum high-sensitivity C-reactive protein (hs-CRP) levels in 39 type 2 diabetic patients with macrovascular complications and 42 type 2 diabetic patients without macrovascular complications matched for age,sex and duration of diabetes ,as well as in 37 healthy control subjects. 2 . serum high-sensitivity CRP (hs-CRP) and serum MBL levels were measured before and after the rosiglitazon and metformin treatment. Results: 1. The frequent of expression MBL gene were similar in patients with all type 2 diabetic patients (including 2 type diabetic patients without macrovascular complications and(or) type 2 diabetic patients with macrovascular complications) and healthy control subjects. 2. Median serum MBL concentrations were significantly lower in patients without macrovascular complications than in patients with macrovascular complications. 0.4468±0.2378mg/L vs. 0.7316±0.2378mg/L, p=0.000. 3 hs-CRP levels in type 2 DM patients were higher than those of normal controls ( P < 0. 01) , but there was nosignificant difference among hs-CRP levels in type 2 diabetes with or without macrovascular complications (P>0.05). 3 .After patients without macrovascular complications had received rosiglitazon and metformi for 12 weeks, Median serum MBL and hs-CRP were significantly decreased .Conclution: 1. The results indicated that there may be no relation between the frequent of expression MBL with type 2 diabetic patients without macrovascular complications and(or) type 2 diabetic patients with macrovascular complications.2. Raising Median serum MBL may have relation with diabetic macroangiopathy. 3.hs-CRP levels in type 2 DM patients without macrovascular complications and 2 DM patients presenting with macrovascular disease were higher than those of normal controls .4. After patients without macrovascular complications had received rosiglitazon and metformin for 12 weeks ,Median serum MBL and hs-CRP were significantly decreased.